LDS/Medical Tests/Methamphetamine, Urine

Methamphetamine, Urine

Methamphetamine is an enantiomeric compound, meaning that it is present in isometric forms that are mirror images of one another. This is important because one isomer, (R-) is present in over-the-counter nasal decongestants and the other isomer (S+) is present in illicit methamphetamine; this becomes important when determining the source of methamphetamine present in a biological specimen.

Methamphetamine is a very potent CNS stimulant, is highly addictive, and acts in the CNS by displacing dopamine from nerve terminal storage vesicles. Methamphetamine can be taken orally, snorted, injected or smoked. The increasing abuse of this drug led to the classification of Schedule II controlled substances for methamphetamine. As mentioned above, some of the clinical uses of this compound are as decongestants and also appetite suppressants.

Methamphetamine is the most commonly abused of the class of drugs known as amphetamines/Sympathomimetic amines. Methamphetamine, as with many of the amphetamines class of compounds, can be readily synthesized from ephedrine. That is why today ephedrine is tracked at pharmacies across the US when purchasing decongestants—each person must show their driver’s license upon purchase and a record is entered into a monitored database.

Since amphetamines such as methamphetamine are known as CNS stimulants, they are also one of the more common drugs of abuse. They are both psychologically and physiologically addicting. Side effects include excitement, alertness, euphoria, decreased appetite, and reduced sense of fatigue. At low doses the individual can experience irritability, anxiety, insomnia, blurred vision, increased blood pressure, and heart palpitations. Chronic high dose users may develop a psychosis that can be indistinguishable from acute schizophrenia. Those who smoke or inject methamphetamine report a brief, intense sensation, or rush. Oral ingestion or snorting produces a long-lasting high instead of a rush, which reportedly can continue for as long as half a day. Methamphetamine is rapidly absorbed from the gastrointestinal tract and widely distributed throughout the body.

Methamphetamine is metabolized via the liver and can remain detectable in urine 3-4 days after ingestion by techniques such as Immunoassay (IA), Gas Chromatography/Mass spectroscopy (GC/MS), and Liquid Chromatography/Mass Spectroscopy (LC/MS).

  • Therapeutic monitoring in blood
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient compliance
A qualitative positive result from an immunoassay (IA) type test indicates only the presence of methamphetamine and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC/MS or LC/MS. Additionally, a number of drugs are metabolized to amphetamine or methamphetamine. These include Adderall, Dexedrin, Deprenyl, and Didrex.

Therapeutic concentration in blood: 10-50 ng/mL
Toxic concentration: >500 ng/mL
Fatal concentration: variable

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration is preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are generally used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as IA, or a quantitative method such as GC/MS or LC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Immunoassay (IA), Gas Chromatography/Mass Spectroscopy (GC/MS), or Liquid Chromatography/Mass Spectroscopy (LC/MS). The main method of quantification is via LC/MS. This particular method of analysis can be used to detect various compounds such as methamphetamine. Methamphetamine can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step may be required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is generally preferred over acid hydrolysis.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 7-14 days
  • Frozen: 30 days
Pharmacogenetic testing, such as genotyping *CYP2D6,* which is partially responsible for metabolism of methamphetamine, may be useful. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Levine, Barry (Ed). Amphetamines/Sympathomimetic Amines. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013: 353-371.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
  • Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.